Literature DB >> 25953090

Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs.

Ying Fan1, Xiaoyan Ding, Jiayu Wang, Fei Ma, Peng Yuan, Qing Li, Pin Zhang, Binghe Xu.   

Abstract

PURPOSE: This study aimed to evaluate the associations between metabolic syndrome (MS) and its components at initial diagnosis and outcomes of breast cancer including triple-negative breast cancer (TNBC) and non-TNBC.
METHODS: A cohort of 1,391 patients was reviewed between January 2004 and July 2008 (including 394 TNBC and 855 non-TNBC cases). MS and its components including body mass index (BMI), serum high-density lipoprotein (HDL) and triglycerides (TG) and their relationships with clinical outcomes were analyzed and then compared between groups.
RESULTS: The incidences of MS and its components including BMI, the levels of HDL and TG were not differently distributed between the 2 groups (all p's >0.05). However, more TNBC than non-TNBC patients presented with hypertension and elevated serum glucose (20.3% vs. 14.9% and 16.0% vs. 10.8%, p = 0.018 and p = 0.012, respectively). TNBC patients had poorer 5-year relapse-free survival (RFS) than non-TNBC patients (72.8% vs. 84.2%, p<0.0001). Only in the TNBC group, patients with low high-density lipoprotein (HDL) demonstrated worse RFS and overall survival (OS; p<0.0001). Multivariate analysis identified that low HDL was an independent worse prognostic factor for both RFS (hazard ratio [HR] = 3.266, 95% confidence interval [95%CI], 2.087-5.112, p<0.0001) and OS (HR = 3.071, 95%CI, 1.732-5.445, p<0.0001) in TNBC patients.
CONCLUSIONS: Decreased level of HDL may predict worse outcomes both in terms of RFS and OS for TNBC patients but not for non-TNBC patients. Further investigations are warranted to detect the underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953090     DOI: 10.5301/jbm.5000143

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  16 in total

1.  Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.

Authors:  Daniel T Dibaba; Kemi Ogunsina; Dejana Braithwaite; Tomi Akinyemiju
Journal:  Breast Cancer Res Treat       Date:  2018-11-21       Impact factor: 4.872

2.  Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative.

Authors:  Michael S Simon; Jennifer L Beebe-Dimmer; Theresa A Hastert; JoAnn E Manson; Elizabeth M Cespedes Feliciano; Marian L Neuhouser; Gloria Y F Ho; Jo L Freudenheim; Howard Strickler; Julie Ruterbusch; Ana Barac; Rowan Chlebowski; Bette Caan
Journal:  Cancer       Date:  2018-01-16       Impact factor: 6.860

3.  Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.

Authors:  Sumadi Lukman Anwar; Roby Cahyono; Dayat Prabowo; Widya Surya Avanti; Lina Choridah; Ery Kus Dwianingsih; Wirsma Arif Harahap; Teguh Aryandono
Journal:  BMC Cancer       Date:  2021-05-22       Impact factor: 4.430

4.  The Clinical Value of Lipid Abnormalities in Early Stage Cervical Cancer.

Authors:  Haiyan Zhu; Anyang Li; Qi Jiang; Luhui Wang; Mengya Jin; Yueyao Shou
Journal:  Int J Gen Med       Date:  2022-04-11

5.  The Effect of Preoperative Apolipoprotein A-I on the Prognosis of Surgical Renal Cell Carcinoma: A Retrospective Large Sample Study.

Authors:  Shengjie Guo; Xiaobo He; Qian Chen; Guangwei Yang; Kai Yao; Pei Dong; Yunlin Ye; Dong Chen; Zhiling Zhang; Zike Qin; Zhuowei Liu; Zaishang Li; Yunfei Xue; Meng Zhang; Ruiwu Liu; Fangjian Zhou; Hui Han
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

6.  Preoperative serum lipid profile and outcome in nonmetastatic colorectal cancer.

Authors:  Ting-Ting Hong; Di Shen; Xiao-Ping Chen; Xiao-Hong Wu; Dong Hua
Journal:  Chronic Dis Transl Med       Date:  2016-12-22

7.  A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections.

Authors:  Lu Tian; Qian Yu; Xing-Hui Gao; Jiong Wu; Xiao-Lu Ma; Qian Dai; Chun-Yan Zhang; Yan Zhou; Yi-Chi Zhang; Bai-Shen Pan; Jian Zhou; Jia Fan; Xin-Rong Yang; Wei Guo
Journal:  Lipids Health Dis       Date:  2017-06-26       Impact factor: 3.876

Review 8.  Emerging roles of low-density lipoprotein in the development and treatment of breast cancer.

Authors:  Xuefeng Guan; Zhuo Liu; Zhen Zhao; Xuefeng Zhang; Siteng Tao; Bao Yuan; Jiabao Zhang; Dawei Wang; Qing Liu; Yu Ding
Journal:  Lipids Health Dis       Date:  2019-06-10       Impact factor: 3.876

9.  Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients.

Authors:  Danian Dai; Bo Chen; Bin Wang; Hailin Tang; Xing Li; Zhiping Zhao; Xuan Li; Xiaoming Xie; Weidong Wei
Journal:  J Cancer       Date:  2016-08-07       Impact factor: 4.207

10.  Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.

Authors:  Trygve Lofterød; Elin S Mortensen; Hawa Nalwoga; Tom Wilsgaard; Hanne Frydenberg; Terje Risberg; Anne Elise Eggen; Anne McTiernan; Sura Aziz; Erik A Wist; Andreas Stensvold; Jon B Reitan; Lars A Akslen; Inger Thune
Journal:  BMC Cancer       Date:  2018-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.